# OnCo record nci9673 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nci9673/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nci9673", "NCT02314169" ;
  schema:name "NCI9673"@en ;
  schema:alternateName "NCI 9673"@en, "ETCTN 9673"@en ;
  schema:description "NCI9673 was the first completed immunotherapy trial in anal cancer: nivolumab on its own shrank tumours in a quarter of heavily treated patients, which made PD-1 blockade a standard later option, but the follow-on randomisation showed that adding ipilimumab did not help and added toxicity."@en ;
  schema:url <https://onco.cc/trials/nci9673/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02314169> ;
  onco:status "mixed" ;
  onco:tag "soc-trials" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/metastatic-anal-cancer/>, <https://onco.cc/cancers/anal/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/> ;
  onco:institutions <https://onco.cc/institutions/md-anderson/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-nci9673-nivolumab-metastatic-anal-cancer-morris-lancet-oncol-2017/>, <https://onco.cc/key-papers/paper-nci9673-part-b-nivolumab-ipilimumab-anal-cancer-morris-jco-2026/> .